Skip to contentHome page Seeking Alpha - Power to InvestorsSep. 21, 2025 8:44 AM ETEli Lilly and Company (LLY) StockNVO, GPCR, VKTX, LLY:CA, NONOF, NVON:CA, LLYTerry ChrisomalisInvesting Group LeaderSummaryEli Lilly is well-positioned for continued growth, driven by strong sales of Zepbound and Mounjaro in obesity and type 2 diabetes.Company is expanding Mounjaro's label to include children and adolescents with T2D, following positive phase 3 SURPASS-PEDS trial results and global regulatory submissions.Orforglipron, LLY's oral GLP-1 agonist, outperformed Novo Nordisk's oral semaglutide in phase 3 ACHIEVE-3 study, with regulatory filings planned for T2D and obesity 2026.Given robust sales, pipeline catalysts, and expansion opportunities, LLY stock is rated a "Buy" for its growth potential in diabetes and obesity markets; Especially with orforglipron in place.Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More »Jacob Wackerhausen/iStock via Getty ImagesEli Lilly (NYSE:LLY) continues to be a powerhouse in the obesity and type 2 diabetes [T2D] treatment spaces due to approvals of Zepbound and Mounjaro, respectively. I believe that there are expansion opportunities in these twoMore on my IG serviceThis article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.This article was written byTerry Chrisomalis13.72K FollowersTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsRecommended For YouAbout LLY StockSymbolLast Price% Chg1D5D1M6M1Y5Y10YMarket CapRev Growth (YoY)Short InterestPrev. CloseMore on LLYRelated StocksSymbolLast Price% Chg--1D5D1M6M1Y5Y10YTrending AnalysisTrending NewsSeeking Alpha - Power to InvestorsPower to InvestorsFollow usDownload appContact usSubscription Support: 1-347-509-6837© 2025 Seeking AlphaTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.